News

Public · Published

Exicom Q2 Revenue Rises 21.3% To Rs 277 Cr; Board Approves Tritium Divestment

Exicom Tele-Systems reported standalone second-quarter FY27 revenue up 21.3% year on year to Rs 277 crore, driven by growth in EV charging. Its board approved the proposed divestment of Tritium, its global DC fast-charging business, at an indicative enterprise valuation of USD 85 million; the sale is not final.

Published:

Updated:

What happened

Exicom Tele-Systems reported standalone second-quarter FY27 revenue up 21.3% year on year to Rs 277 crore, driven by growth in EV charging. Its board approved the proposed divestment of Tritium, its global DC fast-charging business, at an indicative enterprise valuation of USD 85 million; the sale is not final.

Proposed

Global impact / market context

Growth in EV charging helped lift standalone revenue and earnings, while consolidated EBITDA, a measure of operating performance before financing and certain accounting costs, moved from a loss to a small profit. The proposed Tritium sale could reshape the business, but the consolidated net loss remains a concern.

Analyst inference

The reported figures show stronger revenue and operating results alongside a consolidated net loss, so the improvement is uneven across the company. The sale valuation is indicative, not a completed transaction price, and the supplied report gives no approval timeline or expected use of proceeds.

Analyst inference

What to watch

  1. Look for whether the proposed Tritium sale receives required approvals and closes; until then, the indicative USD 85 million enterprise valuation does not represent completed proceeds. Analyst inference
  2. Check upcoming results for whether EV charging revenue remains above Rs 100 crore per quarter and whether higher charger production converts into sustained sales and earnings. Analyst inference
  3. Track consolidated net results alongside positive EBITDA: the company reported a Rs 57.8 crore net loss despite consolidated EBITDA of Rs 1.8 crore. Confirmed

Evidence

  • Original source link unavailable